
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443538511
| IUPAC_name = 8-Chloro-11-(4-methylpiperazin-1-yl)-5''H''-dibenzo[''b'',''e''][1,4]diazepine
| image = Clozapine.svg
| width = 200
| alt = Skeletal formula of clozapine
| image2 = Clozapine 3D ball.png
| alt2 = Stick-and-ball model of the clozapine molecule

<!--Clinical data-->
| tradename = Clozaril, Leponex, Versacloz, others<ref name=brands/>
| Drugs.com = {{drugs.com|monograph|clozapine}}
| MedlinePlus = a691001
| pregnancy_AU = C
| pregnancy_US = B
| pregnancy_US_comment = <ref name=AHFS2015/>
| legal_AU = S4
| legal_US = Rx-only
| routes_of_administration = by mouth
| class = {{tsl|en|atypical antipsychotic||atypical antipsychotic}}

<!--Pharmacokinetic data-->
| bioavailability = 60 to 70%
| metabolism = [[肝臟|Liver]], by several [[细胞色素P450|CYP]] [[同工酶|isozyme]]s
| elimination_half-life = 6 to 26 hours (mean value 14.2 hours in steady state conditions)
| excretion = 80% in metabolized state: 30% biliary and 50% [[腎|kidney]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 5786-21-0
| ATC_prefix = N05
| ATC_suffix = AH02
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3766
| PubChem = 2818
| IUPHAR_ligand = 38
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00363
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10442628
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J60AR2IKIC
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00283
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 42

<!--Chemical data-->
| C=18 | H=19 | Cl=1 | N=4
| SMILES = CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QZUDBNBUXVUHMW-UHFFFAOYSA-N
| melting_point = 183
| solubility = 0.1889<ref name ="Hopfinger">{{cite journal |vauthors=Hopfinger A, Esposito EX, Llinas A, Glen RC, Goodman JM |title = Findings of the Challenge To Predict Aqueous Solubility |journal = Journal of Chemical Information and Modeling |volume = 49 |pages = 1–5 |year = 2009 |doi=10.1021/ci800436c|pmid=19117422}}</ref>
}}
{{medical}}

<!-- Definition and medical uses -->
'''氯氮平'''（Clozapine），常見商標名Clozaril<ref name=brands/>，為一種{{tsl|en|atypical antipsychotic|非典型抗精神病藥物}}<ref name=AHFS2015>{{cite web|title=Clozapine|url=https://www.drugs.com/monograph/clozapine.html|publisher=The American Society of Health-System Pharmacists|accessdate=Dec 1, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20151208103801/http://www.drugs.com/monograph/clozapine.html|archivedate=2015-12-08|df=}}</ref>。主要用於治療其他精神科藥物治療無效的[[精神分裂症|精神分裂症]]<ref name=AHFS2015/>。精神分裂症及[[分裂情感性障碍|分裂情感性障碍]]用藥可能會增加[[自殺|自殺]]的機會<ref name=AHFS2015/>。本品藥效較其他{{tsl|en|typical antipsychotics|典型抗精神病藥物}}為強，因此可用於治療對於其他藥物產生抗性的患者<ref name=Lancet2013>{{cite journal |last1=Leucht |first1=Stefan |last2=Cipriani |first2=Andrea |last3=Spineli |first3=Loukia |last4=Mavridis |first4=Dimitris |last5=Örey |first5=Deniz |last6=Richter |first6=Franziska |last7=Samara |first7=Myrto |last8=Barbui |first8=Corrado |last9=Engel |first9=Rolf R |last10=Geddes |first10=John R |last11=Kissling |first11=Werner |last12=Stapf |first12=Marko Paul |last13=Lässig |first13=Bettina |last14=Salanti |first14=Georgia |last15=Davis |first15=John M |title=Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis |journal=The Lancet |volume=382 |issue=9896 |pages=951–62 |year=2013 |pmid=23810019 |doi=10.1016/S0140-6736(13)60733-3 }}</ref><ref>{{cite journal|last1=Essali|first1=A|last2=Al-Haj Haasan|first2=N|last3=Li|first3=C|last4=Rathbone|first4=J|title=Clozapine versus typical neuroleptic medication for schizophrenia.|journal=The Cochrane Database of Systematic Reviews|date=21 January 2009|issue=1|pages=CD000059|pmid=19160174|doi=10.1002/14651858.CD000059.pub2}}</ref><ref>{{cite journal|last1=Siskind|first1=D|last2=McCartney|first2=L|last3=Goldschlager|first3=R|last4=Kisely|first4=S|title=Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.|journal=The British journal of psychiatry : the journal of mental science|date=7 July 2016|pmid=27388573|doi=10.1192/bjp.bp.115.177261|volume=209|pages=385–392}}</ref>。本品由口服給藥<ref name=AHFS2015/>。

<!-- Side effects -->
本品可能會增加發生{{tsl|en|agranulocytosis|粒細胞缺乏症}}的風險，可能會導致死亡<ref name=AHFS2015/>。為了降低不良反應的風險，用藥時最好進行血液監測<ref name=AHFS2015/>。其他嚴重副作用包含[[癲癇發作|癲癇發作]]、[[心肌炎|心肌炎]]、[[高血糖|高血糖]]。因[[失智症|失智症]]導致精神錯亂的年長者用藥可能增加死亡的風險<ref name=AHFS2015/><ref name=Hart2012>{{cite journal|last1=Hartling|first1=L|last2=Abou-Setta|first2=AM|last3=Dursun|first3=S|last4=Mousavi|first4=SS|last5=Pasichnyk|first5=D|last6=Newton|first6=AS|title=Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.|journal=Annals of Internal Medicine|date=2 October 2012|volume=157|issue=7|pages=498–511|pmid=22893011|doi=10.7326/0003-4819-157-7-201210020-00525}}</ref>。常見副作用包含{{tsl|en|sedation|鎮靜|昏睡}}、口乾、[[低血壓|低血壓]]、視覺障礙，以及[[頭暈|頭暈]]等等<ref name=AHFS2015/>。有5%的人用藥後會產生{{tsl|en|tardive dyskinesia|遲發性運動不能}}等永久性動作障礙的風險<ref name=Hart2012/>。其藥理作用迄今尚未明朗<ref name=AHFS2015/>。

<!-- History, society and culture -->
氯氮平於1958年首次合成，並於1972年開始上市<ref name=Cri2007>{{Cite journal|last=Crilly|first=John|date=2007-03-01|title=The history of clozapine and its emergence in the US market a review and analysis|url=http://hpy.sagepub.com/content/18/1/39|journal=History of Psychiatry|language=en|volume=18|issue=1|pages=39–60|doi=10.1177/0957154X07070335|issn=0957-154X|pmid=17580753|deadurl=no|archiveurl=https://web.archive.org/web/20160710221610/http://hpy.sagepub.com/content/18/1/39|archivedate=2016-07-10|df=}}</ref>，為第一種典型抗精神病藥物<ref name=Cor2013>{{cite book|last1=Corey|first1=edited by Jie Jack Li, E.J.|title=Drug discovery practices, processes, and perspectives|date=2013|publisher=John Wiley & Sons|location=Hoboken, N.J.|isbn=9781118354469|page=248|url=https://books.google.com/books?id=mIyxO5cLEAcC&pg=PA248|deadurl=no|archiveurl=https://web.archive.org/web/20170908171042/https://books.google.com/books?id=mIyxO5cLEAcC&pg=PA248|archivedate=2017-09-08|df=}}</ref>。本品列名於[[世界卫生组织基本药物标准清单|世界卫生组织基本药物标准清单]]之中，為基礎公衛體系必備藥物之一<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref>。本品屬於[[通用名药物|通用名药物]]<ref name=AHFS2015/>。在2014年，其每日劑量於[[发展中国家|发展中国家]]的批發價約介於0.05和2.10美金之間<ref>{{cite web|title=Clozapine|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=894&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=2 December 2015|deadurl=yes|archiveurl=https://web.archive.org/web/20180122072854/http://mshpriceguide.org/en/single-drug-information/?DMFId=894&searchYear=2014|archivedate=2018年1月22日}}</ref>

== 医疗用途 ==
氯氮平是一种第二代抗精神病药物。它主要用於治療對其他抗精神病药物无反应或不能容忍的患者。<ref name="ReferenceB">{{cite journal|title=Clozapine versus typical neuroleptic medication for schizophrenia.|first1=A|last2=Al-Haj Haasan|first2=N|date=21 January 2009|journal=The Cochrane Database of Systematic Reviews|issue=1|doi=10.1002/14651858.CD000059.pub2|pages=CD000059|pmid=19160174|last3=Li|first3=C|last4=Rathbone|first4=J|last1=Essali}}</ref> 这意味着他们没有對至少两个不同的的[[抗精神病药|抗精神病药物]]有令人满意的反應。<ref>{{cite journal|title=Treatment-resistant schizophrenia--the role of clozapine|journal=Current Medical Research and Opinion|issue=1|doi=10.1185/03007999709113338|year=1997|volume=14|pages=1–20|pmid=9524789|vauthors=Meltzer HY}}</ref> 它能比第一代抗精神病药物更有效地减少了精神分裂症的症状。它對那些對其他藥物反應不佳的患者有更明顯的效果。<ref name=Lancet2013/>

在一項2013年的研究中，比較了15種抗精神病藥物治療精神分裂症症狀的有效度，[[氯氮平|氯氮平]]排名第一，並且表現出非常高的療效。 它比[[氨磺必利|氨磺必利]]（排名第二）有效25％，比[[奥氮平|奧氮平]]（排名第三）有效33％，有效程度是[[氟哌啶醇|氟哌啶醇]]，[[喹硫平|喹硫平]]和[[阿立哌唑|阿立哌唑]]的兩倍。<ref name="Lancet2013">{{cite journal|title=Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis|first1=Stefan|last2=Cipriani|first2=Andrea|journal=The Lancet|issue=9896|doi=10.1016/S0140-6736(13)60733-3|year=2013|volume=382|pages=951–62|pmid=23810019|last3=Spineli|first3=Loukia|last4=Mavridis|first4=Dimitris|last5=Örey|first5=Deniz|last6=Richter|first6=Franziska|last7=Samara|first7=Myrto|last8=Barbui|first8=Corrado|last9=Engel|first9=Rolf R|last1=Leucht|last10=Geddes|first10=John R|last11=Kissling|first11=Werner|last12=Stapf|first12=Marko Paul|last13=Lässig|first13=Bettina|last14=Salanti|first14=Georgia|last15=Davis|first15=John M}}</ref>

然而，氯氮平的作用並非（至少在短期內）反映在整體的衡量標準中，例如能力离开医院和保持就业。 患者复发率是低的，患者可接受性是較其他抗精神病藥物好。<ref name="ReferenceB">{{cite journal|title=Clozapine versus typical neuroleptic medication for schizophrenia.|first1=A|last2=Al-Haj Haasan|first2=N|date=21 January 2009|journal=The Cochrane Database of Systematic Reviews|issue=1|doi=10.1002/14651858.CD000059.pub2|pages=CD000059|pmid=19160174|last3=Li|first3=C|last4=Rathbone|first4=J|last1=Essali}}</ref> 有一些證據表明氯氮平可能會降低[[精神分裂症|精神分裂症]]患者[[濫用藥物|濫用藥物]]的傾向。<ref>{{cite journal|title=Clozapine and substance abuse in patients with schizophrenia|journal=Canadian Journal of Psychiatry|year=1998|volume=43|pages=855–856|vauthors=Lee M, Dickson RA, Campbell M, Oliphant J, Gretton H, Dalby JT}}</ref>

它在同時治療患有[[精神分裂症|精神分裂症]]和[[帕金森氏症|帕金森氏病]]的患者上比其他抗精神病药物更有效.<ref>{{cite web|url=http://asp.cumc.columbia.edu/psych/asktheexperts/ask_the_experts_inquiry.asp?SI=146|title=How would you treat someone who has both schizophrenia and Parkinson's disease?|deadurl=no|archiveurl=https://web.archive.org/web/20131211053108/http://asp.cumc.columbia.edu/psych/asktheexperts/ask_the_experts_inquiry.asp?SI=146|archivedate=2013-12-11|df=}}</ref>

氯氮平不建议用于治疗的老人的[[認知障礙症|認知障礙]]的行为问题

== 副作用 ==
氯氮平可能造成用一些是嚴重和致命的副作用。 常见副作用包括 [[便秘|便秘]]，尿床，睡眠時[[Drooling|流口水]]，[[遲發性肌肉痛|肌肉僵硬]]，昏昏欲睡，[[顫抖|顫抖]]，[[姿位性低血壓|姿位性低血压]]，高血糖和[[Weight_gain|体重增加]]的。有風險會发展成[[錐體外症候群|錐體外症候群]]，例如[[Tardive_dyskinesia|迟发运动障碍]]的風險是低于典型的抗精神病药物；这可能是由于氯氮平的抗膽鹼的影响。 患者從另一種抗精神病藥轉用氯氮平後，錐體外系症狀可能會有所減輕。<ref>{{cite web|url=https://sites.google.com/site/pharmacologymcqs/clozapine-clozaril|title=Clozapine|deadurl=no|archiveurl=https://web.archive.org/web/20131110214051/https://sites.google.com/site/pharmacologymcqs/clozapine-clozaril|archivedate=2013-11-10|df=}}</ref>

氯氮平携带五个黑箱警告，包括粒细胞缺乏，中央神经系统的抑郁症，[[白细胞减少症|白细胞减少症]]，[[嗜中性白血球低下|粒细胞减少症]]，癫痫症，[[骨髓抑制|骨髓抑制]]，[[失智症|認知障礙症]]，[[低血壓|低血压]]、[[心肌炎|心肌炎]]、[[姿位性低血壓|低血压直立性]] （可能有[[昏厥|晕厥]]）和[[癫痫|癲癇]]。<ref>{{cite web|url=http://www.clinicalpharmacology-ip.com/Forms/Monograph/monograph.aspx?cpnum=142&sec=monadve|title=Clinical Pharmacology|author=|date=|website=www.clinicalpharmacology-ip.com}}</ref> 癲癇發作閾值的降低可能與劑量相關，並且較少初始的劑量可降低癲癇發作的風險。較少初始的劑量也可降低直立性低血壓和其他不良心血管副作用的風險。<ref name="MCQ">{{Cite web|url=https://sites.google.com/site/pharmacologymcqs/clozapine-clozaril|title=Clozapine|deadurl=no|archiveurl=https://web.archive.org/web/20131110214051/https://sites.google.com/site/pharmacologymcqs/clozapine-clozaril|archivedate=2013-11-10|df=}}</ref>

許多服用本品男性患者在性高潮期間會停止射精，儘管這在官方藥物指南中沒有記載。<ref>{{cite journal|title=Sexual dysfunction in schizophrenia: focus on recent evidence|date=Apr 2008|journal=Human Psychopharmacology|issue=3|doi=10.1002/hup.924|volume=23|pages=201–209|pmc=|pmid=18338766|vauthors=Baggaley M}}</ref>

然而，许多副作用是可以被管理的，并不一定須要停藥。<ref>{{cite journal|title=Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?|date=Jun 2013|journal=The Journal of Clinical Psychiatry|issue=6|doi=10.4088/JCP.12r08064|volume=74|pages=603–13|pmid=23842012|vauthors=Nielsen J, Correll CU, Manu P, Kane JM}}</ref>

=== 粒细胞缺乏症 ===
氯氮平帶有粒細胞缺乏症的黑箱警告。 在沒有監測的情況下，在治療的最初幾個月內服用氯氮平的人中約有1％發生粒細胞缺乏症;<ref name="GoodmanGilman">{{cite book|last=Baldessarini|first=Ross J.|author2=Frank I. Tarazi|editor=Laurence Brunton|editor2=John Lazo|editor3=Keith Parker|title=Goodman & Gilman's The Pharmacological Basis of Therapeutics|edition=11th|year=2006|publisher=[[McGraw-Hill|McGraw-Hill]]|location=New York|isbn=978-0-07-142280-2|pages=|chapter=[[Pharmacotherapy|Pharmacotherapy]] of [[Psychosis|Psychosis]] and [[Methacrylic_acid|Maa]]|oclc=150149056|title-link=Goodman & Gilman's The Pharmacological Basis of Therapeutics}}</ref> 治療開始的風險在治療後約三個月最高，之後大幅降低，一年後降至0.01％以下。<ref name="Alvir1993">{{cite journal|title=Clozapine-induced agranulocytosis. Incidence and risk factors in the United States|date=Jul 1993|journal=The New England Journal of Medicine|issue=3|doi=10.1056/NEJM199307153290303|volume=329|pages=162–7|pmid=8515788|vauthors=Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA}} [http://content.nejm.org/cgi/content/full/329/3/162 Free full text with registration] {{webarchive|url=https://web.archive.org/web/20071020230040/http://content.nejm.org/cgi/content/full/329/3/162|date=2007-10-20}}</ref> 在試驗中，兒童和青少年以及老年人患有白細胞衰退的潛在風險似乎比年輕人或中年人更常見。 {{citation needed|date=February 2017}}

[[粒细胞缺乏症|粒细胞缺乏症]]是可逆轉的。<ref>{{cite journal|title=Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review|date=Oct 2013|journal=Journal of Child and Adolescent Psychopharmacology|issue=8|doi=10.1089/cap.2013.0050|volume=23|pages=516–21|pmid=24111981|vauthors=Midbari Y, Ebert T, Kosov I, Kotler M, Weizman A, Ram A}}</ref>

=== 對心脏的毒性 ===
心肌炎有时是氯氮平致命的副作用，这通常在使用本品第一个月内开始。<ref>{{cite journal|title=Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003|journal=Drug Safety|issue=1|doi=10.2165/00002018-200730010-00005|year=2007|volume=30|pages=47–57|pmid=17194170|vauthors=Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, Stephan K, McNeil J}}</ref> 疾病的首要表現是發燒，可能伴有與[[上呼吸道感染|上呼吸道]]，[[腸胃炎|胃腸道]]或[[泌尿道感染|泌尿道感染]]相關的症狀。 [[C反應蛋白|C-反應蛋白]]（CRP）通常隨著[[發燒|發燒]]的發生而增加，並且心肌酶，[[肌钙蛋白|肌鈣蛋白]]的增加在5天后發生。 監測指南建議在使用本品開始後的前4週檢查每週的CRP和肌鈣蛋白保持在基線，並觀察患者的疾病症徵和症狀。<ref>{{cite journal|title=A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls|date=Jun 2011|journal=The Australian and New Zealand Journal of Psychiatry|issue=6|doi=10.3109/00048674.2011.572852|volume=45|pages=458–465|pmid=21524186|vauthors=Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ}}</ref> [[心力衰竭|心力衰竭]]是不太常見的，但可能隨著[[肌鈣蛋白|肌鈣蛋白]]的增加而出現。最近有一項病例對照研究發現，隨著氯氮平劑量、年齡和[[丙戊酸鈉|丙戊酸鈉]]的增加，氯氮平誘發[[心肌炎|心肌炎]]的風險會增加。<ref>{{cite journal|title=Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study|date=Nov 2012|journal=Schizophrenia Research|issue=2–3|doi=10.1016/j.schres.2012.08.018|volume=141|pages=173–8|pmid=23010488|vauthors=Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ}}</ref>

=== 胃肠活動 ===
另一個未被認識而可能危及生命的副作用是胃腸運動減少，可能表現為嚴重的[[便秘|便秘]]，[[糞便|糞便]]嵌塞，麻痺性[[腸|腸]]梗阻，腸梗阻，急性巨結腸，[[缺血|缺血]]或[[壞死|壞死]]。<ref>{{cite journal|title=Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases|date=May 2008|journal=The Journal of Clinical Psychiatry|issue=5|doi=10.4088/JCP.v69n0509|volume=69|pages=759–768|pmid=18452342|vauthors=Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M}}</ref> 當使用不透射線標記客觀地測量胃腸功能時，高達80％使用本品的人已經顯示出結腸運動不足。<ref>{{cite journal|title=Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study|date=March 2016|journal=EBioMedicine|doi=10.1016/j.ebiom.2016.02.020|volume=5|pages=125–134|pmc=4816835|pmid=27077119|vauthors=Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, Ellis, PM}}</ref> 目前，氯氮平引起的胃腸動力減少死亡率高於粒細胞增多症。<ref>{{cite journal|title=Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy|date=2012|journal=The Journal of Clinical Psychiatry|issue=10|doi=10.4088/JCP.11r06977|volume=73|pages=1307–1312|pmid=23140648|vauthors=Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF}}</ref> [[考科藍|考科藍]]的一項研究發現很少有證據可以幫助指導關於由氯氮平和其他抗精神病藥物引起的胃腸動力減少的最佳治療方法。<ref>{{cite journal|title=Pharmacological treatment for antipsychotic|date=24 January 2017|journal=The Cochrane Database of Systematic Reviews|issue=1|doi=10.1002/14651858.CD011128.pub2|volume=1|pages=CD011128|pmid=28116777|vauthors=Every-Palmer S, Newton-Howes G, Clarke MJ}}</ref> 監測所有使用氯氮平的人的腸道功能和盡快使用瀉藥已被證明可以改善結腸通過時間並減少嚴重的副作用。<ref>{{cite journal|title=The Porirua Protocol in the treatment of clozapine-induced gastrointestinal hypomotility and constipation: A pre- and post-treatment study|date=January 2017|journal=CNS Drugs|issue=1|doi=10.1007/s40263-016-0391-y|volume=31|pages=75–85|pmid=27826741|vauthors=Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H}}</ref>

=== 唾液分泌過多 ===
雖然氯氮平是M1，M2，M3和M5受體的毒蕈鹼拮抗劑，但也是M4亞群的完全激動劑。 因為M4在唾液腺中高度表達，其M4激動劑活性被認為是造成唾液腺過多的原因。<ref>{{cite web|url=http://www.medscape.com/viewarticle/409612_2|title=Archived copy|accessdate=2010-02-08|deadurl=no|archiveurl=https://web.archive.org/web/20120209042338/http://www.medscape.com/viewarticle/409612_2|archivedate=2012-02-09|df=}}</ref>

=== 中枢神经系统 ===
中枢神经系统的副作用包括 [[昏睡|有睡意]]，[[眩暈_(醫學)|眩晕]]，[[頭痛|头痛]]，[[顫抖|颤抖]]，[[昏厥|晕厥]]，[[睡眠障碍|睡眠障碍，]][[恶梦|恶梦，]]烦躁，[[運動功能減退症|运动不能，]]搅动，[[癲癇發作|癫痫发作]]，痙攣，[[静坐不能|静坐不能]]，神志不清，[[疲勞|疲劳]]，[[失眠|失眠]]，[[Hyperkinesia|运动机能亢进]]，[[虛弱|虛弱]]，昏睡，[[共济失调|共济失调]]，[[合音_(語言學)|説話含糊不清]]，[[抑鬱|抑郁症]]，肌陣攣和[[焦慮|焦虑]]。罕見的副作用有[[妄想|妄想]]，[[幻觉|幻覺]]，[[譫妄|譫妄]]，[[失憶症|失憶]]，[[性欲|性慾]]增加或減少，偏執和煩躁，[[腦電圖|腦電圖]]異常，精神病惡化，感覺異常，癲癇持續狀態和強迫性症狀。與其他抗精神病藥類似，氯氮平很少會引起抗精神病藥物惡性症候群。<ref>[http://www.rxlist.com/cgi/generic/clozapine_ad.htm rxlist.com / Clozapine side effects] {{webarchive|url=https://web.archive.org/web/20071104074526/http://www.rxlist.com/cgi/generic/clozapine_ad.htm|date=2007-11-04}}</ref>

=== 小便失禁 ===
氯氮平與[[尿失禁|尿失禁]]有關，<ref name="Raja">{{cite journal|title=Clozapine safety, 35 years later|date=Jul 2011|journal=Current Drug Safety|issue=3|doi=10.2174/157488611797579230|volume=6|pages=164–184|pmid=22122392|vauthors=Raja M}}</ref> 虽然這並未有共識。<ref>{{cite journal|title=Nocturnal enuresis with antipsychotic medication|date=Jan 2012|journal=The British Journal of Psychiatry|issue=1|doi=10.1192/bjp.bp.111.095737|volume=200|pages=7–9|pmc=|pmid=22215862|vauthors=Barnes TR, Drake MJ, Paton C}}</ref>

=== 戒斷症狀 ===
突然停藥可能導致[[胆碱|膽鹼]][[反位效应|反彈效應]]，嚴重的運動障礙以及嚴重的精神病失代償。 建議患者、家屬和護理人員了解氯氮平突然停藥的症狀和風險。 當停用氯氮平時，建議逐漸減少劑量以降低戒斷效果。<ref name="Ahmed-1998">{{cite journal|title=Clozapine withdrawal-emergent dystonias and dyskinesias: a case series|date=Sep 1998|journal=The Journal of Clinical Psychiatry|issue=9|doi=10.4088/JCP.v59n0906|volume=59|pages=472–7|pmid=9771818|vauthors=Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR}}</ref><ref name="Szafrański-">{{cite journal|title=[Clozapine withdrawal. A review]|journal=Psychiatria Polska|issue=1|doi=|year=1999|volume=33|pages=51–67|pmid=10786215|vauthors=Szafrański T, Gmurkowski K}}</ref>

=== 重量增加及糖尿病 ===
除高血糖外，氯氮平治療的患者體重經常增加。<ref>{{cite journal|title=Novel antipsychotics: comparison of weight gain liabilities|date=Jun 1999|journal=The Journal of Clinical Psychiatry|issue=6|doi=10.4088/JCP.v60n0602|volume=60|pages=358–63|pmid=10401912|vauthors=Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR}}</ref> 葡萄糖代謝受損和肥胖已被證明是代謝綜合徵造成的，並有可能增加心血管疾病的風險。 數據表明氯氮平可能比其他一些第二代[[抗精神病药|抗精神病藥]]更容易引起不良代謝作用。<ref name="pmid17848919">{{cite journal|title=Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles|date=Jan 2008|journal=Molecular Psychiatry|issue=1|doi=10.1038/sj.mp.4002066|volume=13|pages=27–35|pmid=17848919|vauthors=Nasrallah HA}}</ref> 一項研究表明，[[奥氮平|奧氮平]]和[[氯氮平|氯氮平]]使身體優先從脂肪中獲取能量，而不是碳水化合物，來擾亂新陳代謝。碳水化合物水平仍然很高，身體會產生胰島素抵抗並會引起糖尿病。<ref>{{cite journal|title=Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents|date=Jan 2012|journal=Schizophrenia Bulletin|issue=1|doi=10.1093/schbul/sbq053|volume=38|pages=153–166|pmc=3245588|pmid=20494946|vauthors=Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, Breazeale S, Elich TD, Lang CH, Lynch CJ}}</ref>

== 相互作用 ==
[[氟伏沙明|氟伏沙明]]抑制[[氯氮平|氯氮平]]的代謝，導致氯氮平在血液的水平顯著增加。<ref>{{cite journal|title=Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence|date=Dec 1997|journal=Clinical Pharmacokinetics|issue=6|doi=10.2165/00003088-199733060-00004|volume=33|pages=454–71|pmid=9435993|vauthors=Sproule BA, Naranjo CA, Brenmer KE, Hassan PC}}</ref>

當[[卡马西平|卡馬西平]]與氯氮平同時服用時，卡馬西平已被證明可顯著降低氯氮平的血漿水平，從而降低氯氮平的作用。<ref>{{cite journal|title=Carbamazepine-induced changes in plasma levels of neuroleptics|date=Jan 1995|journal=Pharmacopsychiatry|issue=1|doi=10.1055/s-2007-979584|volume=28|pages=26–28|pmid=7746842|vauthors=Tiihonen J, Vartiainen H, Hakola P}}</ref><ref>{{cite journal|title=Interactions between antiepileptic and antipsychotic drug|url=|first1=FM|last2=Berry|first2=D|journal=Drug Saf|issue=2|doi=10.2165/00002018-200629020-00001|year=2006|volume=29|pages=95–118|pmid=16454538|last1=Besag}}</ref> 應監測患者“開始或增加卡馬西平的氯氮平治療效果降低”。 如果停用卡馬西平或降低卡馬西平的[[劑量|劑量]]，應監測氯氮平的治療效果。 有研究建議卡馬西平不要與氯氮平同時使用，因為出現粒細胞增多症的風險增加。<ref>{{cite journal|title=Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence From a Therapeutic Drug Monitoring Service|url=|first1=M|last2=Lindstrom|first2=L|journal=Ther Drug Monit|issue=4|doi=10.1097/00007691-199408000-00006|year=1994|volume=16|pages=368–74|pmid=7974626|last3=Bondesson|first3=U|display-authors=etal|last1=Jerling}}</ref>

已發表的病例報告指出，同時使用[[苯二氮䓬类|苯二氮卓類藥物]]和氯氮平可導致嚴重的不良反應，如[[呼吸中止|呼吸停止]]，[[心搏停止|心臟驟停]]和[[猝死|猝死]]。<ref>{{cite journal|title=Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review|date=Sep 2008|journal=Journal of Psychiatric Practice|issue=5|doi=10.1097/01.pra.0000336753.11943.7c|volume=14|pages=265–70|pmid=18832957|vauthors=Bitter R, Demler TL, Opler L}}</ref>

[[环丙沙星|環丙沙星]]是[[CYP1A2|CYP1A2]]的[[抑制剂|抑製劑]]，氯氮平是主要的[[CYP1A2|CYP1A2]][[酶底物_(生物学)|底物]]。 隨機研究報告了同時服用環丙沙星的精神分裂症患者的氯氮平濃度的升高。<ref>{{cite journal|title=Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia|date=Nov 2000|journal=European Journal of Clinical Pharmacology|issue=8|doi=10.1007/s002280000192|volume=56|pages=585–9|pmid=11151749|vauthors=Raaska K, Neuvonen PJ}}</ref> 因此，當環丙沙星和其他CYP1A2抑製劑加入治療時，氯氮平的處方資料建議“將氯氮平的劑量減少初始劑量的三分之一”，但一旦從治療中停止使用環丙沙星，就建議將氯氮平恢復到原始劑量。<ref>规定的信息。 Clozaril(氯氮平的)。 东Hanover,NJ：诺华医药公司、日2014年。</ref>

== 药理学 ==

=== 药效 ===
{| class="wikitable floatright" style="font-size:small;"
|+氯氮平（及其代謝產物）<ref name="PDSP">{{cite web|title=PDSP K<sub>i</sub> Database|work=Psychoactive Drug Screening Program (PDSP)|author1=Roth, BL|author2=Driscol, J|publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health|accessdate=14 August 2017|url=https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=clozapine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref><ref name="PDSP-2">{{cite web|title=PDSP K<sub>i</sub> Database|work=Psychoactive Drug Screening Program (PDSP)|author1=Roth, BL|author2=Driscol, J|publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health|accessdate=14 August 2017|url=https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=norclozapine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
!位置
!{{abbr|CZP|Clozapine}}
!{{abbrlink|NDMC|N-Desmethylclozapine}}
|-
|5-HT<nowiki><sub id="mwxQ">1A</sub></nowiki>
|123.7
|13.9
|-
|5-HT<nowiki><sub id="mwyw">1B</sub></nowiki>
|519
|406.8
|-
|5-HT<nowiki><sub id="mw0Q">1D</sub></nowiki>
|1,356
|476.2
|-
|5-HT<nowiki><sub id="mw1w">2A</sub></nowiki>
|5.35
|10.9
|-
|[[5-HT2B受體|5-HT<sub>2B</sub>]]
|8.37
|2.8
|-
|5-HT<nowiki><sub id="mw4w">2C</sub></nowiki>
|9.44
|11.9
|-
|5-HT<nowiki><sub id="mw6Q">3</sub></nowiki>
|241
|272.2
|-
|5-HT<nowiki><sub id="mw7w">5A</sub></nowiki>
|3,857
|350.6
|-
|5-HT<nowiki><sub id="mw9Q">6</sub></nowiki>
|13.49
|11.6
|-
|5-HT<nowiki><sub id="mw-w">7</sub></nowiki>
|17.95
|60.1
|-
|[[肾上腺素受体α1A|α<sub>1A</sub>]]
|1.62
|104.8
|-
|α<nowiki><sub id="mwAQc">1B</sub></nowiki>
|7
|85.2
|-
|α<nowiki><sub id="mwAQ0">2A</sub></nowiki>
|37
|137.6
|-
|α<nowiki><sub id="mwARM">2B</sub></nowiki>
|26.5
|95.1
|-
|α<nowiki><sub id="mwARk">2C</sub></nowiki>
|6
|117.7
|-
|β<nowiki><sub id="mwAR8">1</sub></nowiki>
|5,000
|6,239
|-
|β<nowiki><sub id="mwASU">2</sub></nowiki>
|1,650
|4,725
|-
|D<nowiki><sub id="mwASs">1</sub></nowiki>
|266.25
|14.3
|-
|[[多巴胺受體D2|D<sub>2</sub>]]
|157
|101.4
|-
|D<nowiki><sub id="mwATc">3</sub></nowiki>
|269.08
|193.5
|-
|[[多巴胺受体D4|D<sub>4</sub>]]
|26.36
|63.94
|-
|D<nowiki><sub id="mwAUM">5</sub></nowiki>
|255.33
|283.6
|-
|H<nowiki><sub id="mwAUk">1</sub></nowiki>
|1.13
|3.4
|-
|H<nowiki><sub id="mwAU8">2</sub></nowiki>
|153
|345.1
|-
|H<nowiki><sub id="mwAVU">3</sub></nowiki>
|>10,000
|>10,000
|-
|H<nowiki><sub id="mwAVs">4</sub></nowiki>
|665
|1,028
|-
|M<nowiki><sub id="mwAWE">1</sub></nowiki>
|6.17
|67.6
|-
|M<nowiki><sub id="mwAWc">2</sub></nowiki>
|36.67
|414.5
|-
|M<nowiki><sub id="mwAW0">3</sub></nowiki>
|19.25
|95.7
|-
|M<nowiki><sub id="mwAXM">4</sub></nowiki>
|15.33
|169.9
|-
|M<nowiki><sub id="mwAXk">5</sub></nowiki>
|15.5
|35.4
|-
|σ<nowiki><sub id="mwAX8">1</sub></nowiki>
|5,000
|>10,000
|-
|σ<nowiki><sub id="mwAYU">2</sub></nowiki>
|{{abbr|ND|No data}}
|>10,000
|-
|{{abbrlink|MOR|μ-Opioid receptor}}
|1,000
|>10,000
|-
|{{abbrlink|DOR|δ-Opioid receptor}}
|1,000
|127.9
|-
|{{abbrlink|KOR|κ-Opioid receptor}}
|1,000
|>10,000
|-
|{{abbrlink|SERT|Serotonin transporter}}
|1,624
|316.6
|-
|{{abbrlink|NET|Norepinephrine transporter}}
|3,168
|493.9
|-
|{{abbrlink|DAT|Dopamine transporter}}
|>10,000
|>10,000
|- class="sortbottom"
| colspan="3" style="width: 1px;" |值是Ki（nM）。 值越小，藥物與該部位結合的強度越大。 所有數據均為人類克隆蛋白，除σ1（豚鼠），MOR（大鼠），DOR（小鼠）和KOR（豚鼠）外。<ref name="PDSP" /><ref name="PDSP-2" />
|}
氯氮平被歸類為第二代抗精神病藥，因為它與5-羥色胺以及多巴胺受體結合。<ref name="Nahgre01">{{cite journal|title=Focus on clozapine|journal=Current Medical Research and Opinion|issue=3|doi=10.1185/0300799039117069|year=2001|volume=17|pages=223–9|pmid=11900316|vauthors=Naheed M, Green B}}</ref>

氯氮平是5-羥色胺受體5-HT2A亞基的拮抗劑，推測可改善抑鬱，焦慮和與精神分裂症相關的負面認知症狀。<ref>{{cite journal|title=CNS Receptor Partial Agonists: A New Approach to Drug Discovery|author=Robinson DS|url=http://www.primarypsychiatry.com/aspx/articledetail.aspx?articleid=1149|journal=Primary Psychiatry|issue=8|year=2007|volume=14|pages=22–24|archiveurl=https://web.archive.org/web/20120118091113/http://www.primarypsychiatry.com/aspx/articledetail.aspx?articleid=1149|archivedate=2012-01-18|deadurl=no|df=}}</ref><ref>{{cite web|title=clozapine {{!}} C18H19ClN4 - PubChem|url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2818|website=pubchem.ncbi.nlm.nih.gov|accessdate=16 July 2017|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20131224110428/http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2818|archivedate=24 December 2013|df=}}</ref>

氯氮平與[[Γ-氨基丁酸|<font face="-webkit-standard">GABA</font><sub>B</sub>]]受體的直接相互作用被顯示了<ref name="WUY">{{cite journal|title=Evidence that clozapine directly interacts on the GABAB receptor|date=Sep 2011|journal=NeuroReport|issue=13|doi=10.1097/WNR.0b013e328349739b|volume=22|pages=637–41|pmid=21753741|vauthors=Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, Snead OC}}</ref> [[Γ-氨基丁酸A型受体|<font face="-webkit-standard">GABA</font><sub>B</sub>受體]]有缺陷小鼠表現出增加的細胞外[[多巴胺|多巴胺]]水平和改變的運動行為，與[[精神分裂症|精神分裂症]]動物模型相當。<ref name="VCM">{{cite journal|title=Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice|date=May 2006|journal=Journal of Neurochemistry|issue=4|doi=10.1111/j.1471-4159.2006.03806.x|volume=97|pages=979–91|pmid=16606363|vauthors=Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, Waldmeier P, Kaupmann K, Pévet P, Bettler B}}</ref><font face="-webkit-standard">GABA</font><sub>B</sub>受體激動劑和正變構調節劑減少這些模型中的運動變化<ref name="WJM">{{cite journal|title=The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice|date=Jul 2011|journal=British Journal of Pharmacology|issue=5|doi=10.1111/j.1476-5381.2011.01301.x|volume=163|pages=1034–47|pmc=3130949|pmid=21371011|vauthors=Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A}}</ref>

氯氮平誘導[[星形膠質細胞|星形膠質細胞]]釋放[[谷氨酸|谷氨酸]]和D-絲氨酸，這是[[N-甲基-D-天門冬胺酸受體|NMDA]]受體甘氨酸位點的激動劑，<ref name="TAS">{{cite journal|title=Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes|date=Mar 2012|journal=British Journal of Pharmacology|issue=5|doi=10.1111/j.1476-5381.2011.01638.x|volume=165|pages=1543–55|pmc=3372736|pmid=21880034|vauthors=Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M}}</ref> 並減少星形膠質細胞谷氨酸轉運蛋白的表達。 這些直接作用也存在於不含神經元的星形膠質細胞培養物中。 氯氮平可預防由NMDA[[受体拮抗剂|受體拮抗劑]]引起的NMDA受體表達受損。<ref name="XID">{{cite journal|title=Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex|date=May 2011|journal=Neuropsychopharmacology|issue=6|doi=10.1038/npp.2011.12|volume=36|pages=1260–74|pmc=3079418|pmid=21326193|vauthors=Xi D, Li YC, Snyder MA, Gao RY, Adelman AE, Zhang W, Shumsky JS, Gao WJ}}</ref>

=== 药物动力学 ===
[[File:Desmethylclozapine.svg|左]]
[[口服给药|口服給藥]]後，氯氮平幾乎完全被吸收，但由於[[首过效应|首過效應]]，口服[[生物利用度|生物利用度]]僅為60-70％。 口服給藥後達到最高濃度的時間約為2小時30分鐘，食物似乎不影響氯氮平的生物利用度。 氯氮平的[[生物半衰期|生物半衰期]]在穩態條件下約為14小時（隨每日劑量而變化）。

氯氮平在肝臟中通過細胞色素P450系統廣泛代謝為適合在尿液和糞便中消除的極性代謝物。 主要[[代謝產物|代謝產物]]諾氯氮平（去甲基氯氮平）具有藥理學活性。 細胞色素P450[[同工酶|同工酶]]1A2主要負責氯氮平代謝，但2C，2D6,2E1和3A3/4似乎也起作用。誘導（如:香煙煙霧）或抑制（例如茶鹼，環丙沙星，氟伏沙明）[[CYP1A2|CYP1A2]]的藥物可分別增加或減少氯氮平的[[代谢|代謝]]。 例如，吸煙引起的新陳代謝誘導與非[[吸煙|吸煙]]者相比，吸煙者需要高達兩倍的氯氮平劑量才能達到相同的血漿濃度。<ref name="ReferenceA">{{cite journal|title=Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients|date=Feb 2004|journal=Journal of Clinical Psychopharmacology|issue=1|doi=10.1097/01.jcp.0000106221.36344.4d|volume=24|pages=70–8|pmid=14709950|vauthors=Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ}}</ref>

氯氮平和去甲氯苯胺（去甲基 - 氯氮平）的[[血浆|血漿]]水平也可以監測，儘管它們顯示出顯著的變異程度，並且在女性中更高並且隨著年齡的增長而增加。<ref>{{cite journal|title=Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics|date=Jan 1999|journal=The Journal of Clinical Psychiatry|issue=1|doi=10.4088/JCP.v60n0108|volume=60|pages=36–40|pmid=10074876|vauthors=Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW}}</ref> 監測氯氮平和去甲氯平的血漿水平已被證明可用於評估藥物依從性，代謝狀態，預防毒性和改善劑量。<ref name="ReferenceA">{{cite journal|title=Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients|date=Feb 2004|journal=Journal of Clinical Psychopharmacology|issue=1|doi=10.1097/01.jcp.0000106221.36344.4d|volume=24|pages=70–8|pmid=14709950|vauthors=Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ}}</ref>

== 化学 ==
氯氮平是一種二苯並二氮雜卓，其結構與洛沙平有關。 微溶於水，溶於[[丙酮|丙酮]]，極易溶於[[氯仿|氯仿]]。 其在水中的溶解度為0.1889 mg / L（25[[摄氏温标|°C]]）。 其製造商[[诺华|諾華]]聲稱其在水中的溶解度<0.01％（<100 mg / L）。<ref>{{Cite web|last=Novartis Pharmaceuticals|authorlink=Novartis|title=Prescribing Information|url=http://www.rxlist.com/clozaril-drug.htm|format=PDF|accessdate=2007-06-29|date=April 2006|publisher=Novartis Pharmaceuticals|pages=36|deadurl=no|archiveurl=https://web.archive.org/web/20081023052932/http://www.rxlist.com/clozaril-drug.htm|archivedate=2008-10-23|df=}} 
</ref>

== 历史 ==
氯氮平由[[瑞士|瑞士]]製藥公司Wander AG於1958年合成，基於[[三环类抗抑郁药|三環類抗抑鬱藥]]丙咪嗪的[[化學|化學]]結構。 在1962年，在人類身上的第一次測試被認為是失敗。 在1965年和1966年在[[德國|德國]]進行的試驗以及1966年在[[維也納|維也納]]的試驗取得了成功。 在1967年，'''[[山德士|山德士]]'''收購了Wander AG。<ref name="Cri2007"/>進一步的實驗發生在1972年，氯氮平在[[瑞士|瑞士]]和[[奧地利|奧地利]]被推出市面為Leponex。 在兩年後，它於1975年在[[西德|西德]]和[[芬兰|芬蘭]]被推出市面。早期測試在[[美國|美國]]大約同時進行。<ref name="Crilly">{{cite journal|title=The history of clozapine and its emergence in the US market: a review and analysis|date=Mar 2007|journal=History of Psychiatry|issue=1|doi=10.1177/0957154X07070335|volume=18|pages=39–60|pmid=17580753|vauthors=Crilly J}}</ref> 1975年，在一些使用氯氮平的患者發生粒細胞缺乏症導致死亡的報導出現後，氯氮平被製造商自願撤回。<ref>{{cite book|author=Healy, David|title=The Creation of Psychopharmacology|publisher=Harvard University Press|location=Cambridge|year=2004|pages=238–42|isbn=978-0-674-01599-9|url=https://books.google.com/?id=6O2rPJnyhj0C}}</ref> 氯氮平屯在後來十多年來一直失寵，儘管在芬蘭發生的粒細胞缺乏症的原因尚不清楚，它的發生率高出20倍。<ref>{{Cite journal|title=CLOZAPINE AND AGRANULOCYTOSIS|last=Griffith|first=R.W.|last2=Saameli|first2=K.|journal=The Lancet|issue=7936|doi=10.1016/s0140-6736(75)90135-x|year=1975|volume=306|pages=657}}</ref> 這比其他任何國家報吿的都多。 然而，當研究表明氯氮平對治療抵抗性[[精神分裂症|精神分裂症]]比其他[[抗精神病药|抗精神病藥]]更有效時，[[美国食品药品监督管理局|FDA]]和大多數其他國家的衛生當局僅批准其用於治療抵抗性精神分裂症，並且需要限制性分佈，在發生粒細胞缺乏症之前，患者須要登記和定期進行血液學監測來檢測粒細胞減少症。 在2002年12月，氯氮平在美國被批准用於降低精神分裂症或分裂情感患者的自殺風險，這些患者被認為具有自殺行為的慢性風險<ref>{{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19758se1-047ltr.pdf|title=Supplemental NDA Approval Letter for Clozaril, NDA 19-758 / S-047|date=December 18, 2002|publisher=United States Food and Drug Administration|accessdate=November 23, 2012|archiveurl=https://www.webcitation.org/6CP6N7XiP?url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/19758se1-047ltr.pdf|archivedate=November 23, 1012|deadurl=no|df=}}</ref> 2005年FDA批准允許降低血液監測的頻率。<ref>{{cite web|url=http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/019758s054ltr.pdf|title=Archived copy|accessdate=2009-09-20|deadurl=no|archiveurl=https://web.archive.org/web/20110511063325/http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/019758s054ltr.pdf|archivedate=2011-05-11|df=}}</ref>在2015年，個別製造商患者登記處被FDA要求合併到一個名為Clozapine REMS Registry的共享患者登記處。

氯氮平使用很多品牌在全世界销售，包括Alemoxan,Azaleptine,Azaleptol,Cloment,Clonex,Clopin,Clopine,Clopsine,Cloril,Clorilex,Clozamed,Clozapex,Clozapin,Clozapina、Clozapinum,Clozapyl,Clozarem,Clozaril,Denzapine,Dicomex,Elcrit,Excloza,FazaClo,Froidir,Ihope,Klozapol,Lanolept,Lapenax,Leponex,Lodux,Lozapine,Lozatric,Luften,Medazepine,Mezapin,Nirva,Ozadep,Ozapim，Refract，Refraxol,Schizonex,Sensipin,Sequax,Sicozapina, Sizoril,Syclop,Syzopin,Tanyl,Uspen,Versacloz,Xenopal,Zaclo,Zapenia,Zapine,Zaponex,Zaporil,Ziproc，及Zopin。<ref name="brands">{{cite web|title=Clozapine International Brands|url=https://www.drugs.com/international/clozapine.html|publisher=Drugs.com|accessdate=28 February 2017|deadurl=no|archiveurl=https://web.archive.org/web/20170301092935/https://www.drugs.com/international/clozapine.html|archivedate=1 March 2017|df=}}</ref>

*

== 參見 ==
*{{tsl|en|DHA-clozapine||DHA-clozapine}}
*{{tsl|en|Drug of last resort||Drug of last resort}}

== 延伸閱讀==
* Benkert, Hippius: Kompendium der Psychiatrischen Pharmakotherapie （German）, 4th. ed., Springer Verlag
* B. Bandelow, S. Bleich, and S. Kropp: Handbuch Psychopharmaka （German）, 2nd. ed. Hogrefe
* {{cite journal | vauthors = Crilly J | title = The history of clozapine and its emergence in the US market: a review and analysis | journal = History of Psychiatry | volume = 18 | issue = 1 | pages = 39–60 | date = Mar 2007 | pmid = 17580753 | doi = 10.1177/0957154X07070335 }}

== 外部連結 ==
*[http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Clozapine U.S. National Library of Medicine: Drug Information Portal – Clozapine]
* [http://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Clozapine US Package Inserts]

== 參考文獻 ==
{{Reflist}}

{{Antipsychotics}}
{{Mood stabilizers}}
{{Navboxes
| title = [[药物效应动力学|药物效应动力学]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:非典型抗精神病药|Category:非典型抗精神病药]]
[[Category:氯代芳烴|Category:氯代芳烴]]
[[Category:多巴胺激动剂|Category:多巴胺激动剂]]
[[Category:多巴胺拮抗药|Category:多巴胺拮抗药]]
[[Category:情绪稳定剂|Category:情绪稳定剂]]
[[Category:蕈毒碱性受体拮抗剂|Category:蕈毒碱性受体拮抗剂]]
[[Category:哌嗪|Category:哌嗪]]
[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]